| Oral ulcers | 218/222 (98.2%) | 105/107 (98.1%) | 113/115 (98.3%) | 0.94 |
| Skin manifestations | 190/220 (86.4%) | 90/107 (84.1%) | 100/113 (88.5%) | 0.34 |
| Erythema nodosum | 116/218 (53.2%) | 49/105 (46.7%) | 67/113 (59.3%) | 0.06 |
| Acneiform lesions | 113/218 (51.8%) | 65/105 (61.9%) | 48/113 (42.5%) | 0.004 |
| Thrombophlebitis | 11/218 (5.0%) | 5/105 (4.8%) | 6/113 (5.3%) | 0.85 |
| Ocular involvements | 118/222 (53.2%) | 68/108 (63.0%) | 50/114 (43.9%) | 0.004 |
| Genital ulcers | 138/221 (62.4%) | 58/107 (54.2%) | 80/114 (70.2%) | 0.01 |
| Artiritis | 86/223 (38.6%) | 33/108 (30.6%) | 53/115 (46.1%) | 0.02 |
| Gastrointestinal manifestations | 56/223 (25.1%) | 23/108 (21.3%) | 33/115 (28.7%) | 0.20 |
| Neurogenic diseases | 20/223 (9.0%) | 12/108 (11.1%) | 8/115 (7.0%) | 0.28 |
| Vascular involvements | 18/223 (8.1%) | 6/108 (5.6%) | 12/115 (10.4%) | 0.18 |
| HLA-B51 positive | 51/123 (41.5%) | 32/62 (51.6%) | 19/61 (31.1%) | 0.02 |
| HLA-A26 positive | 28/116 (24.1%) | 14/56 (25.0%) | 14/60 (23.3%) | 0.91 |